Окрелизумаб (Russian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Окрелизумаб" in Russian language version.

refsWebsite

Global rank Russian rank

1^st place

4^th place

6^th place

5,225^th place

4,631^st place

low place

2^nd place

3^rd place

49^th place

61^st place

2,374^th place

2,377^th place

low place

1,828^th place

clinicaltrials.gov

Clinical trial number NCT00539838 for "A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)" at ClinicalTrials.gov
Clinical trial number NCT00676715 for "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis" at ClinicalTrials.gov

Kausar, F; Mustafa, K; Sweis, G; Sawaqed, R; Alawneh, K; Salloum, R; Badaracco, M; Niewold, TB; Sweiss, N.J. Ocrelizumab: a step forward in the evolution of B-cell therapy (англ.) // Expert opinion on biological therapy : journal. — 2009. — Vol. 9, no. 7. — P. 889—895. — doi:10.1517/14712590903018837. — PMID 19463076.

K. John Morrow Jr (2008-06-15). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 36. Архивировано 13 февраля 2009. Дата обращения: 6 июля 2008. (Note: information included in this article only found in table present in print version of article.)

Kausar, F; Mustafa, K; Sweis, G; Sawaqed, R; Alawneh, K; Salloum, R; Badaracco, M; Niewold, TB; Sweiss, N.J. Ocrelizumab: a step forward in the evolution of B-cell therapy (англ.) // Expert opinion on biological therapy : journal. — 2009. — Vol. 9, no. 7. — P. 889—895. — doi:10.1517/14712590903018837. — PMID 19463076.
Hutas, G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies (англ.) // Current opinion in investigational drugs (London, England : 2000) : journal. — 2008. — Vol. 9, no. 11. — P. 1206—1215. — PMID 18951300.

OCREVUS- ocrelizumab injection (англ.). DailyMed. U. S. National Library of Medicine.